Overview
Daniel Thompson is a Radiologist and an Interventional Radiologist in Newburyport, Massachusetts. Dr. Thompson is rated as an Experienced provider by MediFind in the treatment of Cholestasis. His top areas of expertise are Pleural Effusion, Gallbladder Disease, Cerebelloolivary Atrophy, Gastrostomy, and Liver Embolization. Dr. Thompson is currently accepting new patients.
His clinical research consists of co-authoring 8 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
25 Highland Ave, Newburyport, MA 01950
1 General St, Lawrence, MA 01841
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc
Olga Brook is a Radiologist and an Interventional Radiologist in Boston, Massachusetts. Dr. Brook is rated as a Distinguished provider by MediFind in the treatment of Cholestasis. Her top areas of expertise are Familial Pancreatic Cancer, Visceromegaly, Lung Cancer, Liver Embolization, and Endoscopy.
Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc
Jeffrey Weinstein is an Interventional Radiologist and a Radiologist in Boston, Massachusetts. Dr. Weinstein is rated as an Advanced provider by MediFind in the treatment of Cholestasis. His top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Liver Embolization, and Embolectomy. Dr. Weinstein is currently accepting new patients.
Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc
Marwan Moussa is an Interventional Radiologist and a Radiologist in Boston, Massachusetts. Dr. Moussa has been practicing medicine for over 18 years and is rated as an Experienced provider by MediFind in the treatment of Cholestasis. His top areas of expertise are Cholestasis, Bile Duct Stricture, Bile Duct Obstruction, Liver Embolization, and Cardiac Ablation.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Gallbladder DiseaseDr. Thompson isDistinguished. Learn about Gallbladder Disease.
- Pleural EffusionDr. Thompson isDistinguished. Learn about Pleural Effusion.
- Advanced
- AscitesDr. Thompson isAdvanced. Learn about Ascites.
- Cerebellar DegenerationDr. Thompson isAdvanced. Learn about Cerebellar Degeneration.
- Cerebellar Multiple System AtrophyDr. Thompson isAdvanced. Learn about Cerebellar Multiple System Atrophy.
- Cerebelloolivary AtrophyDr. Thompson isAdvanced. Learn about Cerebelloolivary Atrophy.
- Diverticular DiseaseDr. Thompson isAdvanced. Learn about Diverticular Disease.
- EmphysemaDr. Thompson isAdvanced. Learn about Emphysema.
- Experienced
- Aberrant Subclavian ArteryDr. Thompson isExperienced. Learn about Aberrant Subclavian Artery.
- Acute Arterial Occlusion of KidneyDr. Thompson isExperienced. Learn about Acute Arterial Occlusion of Kidney.
- Adenosine Deaminase 2 DeficiencyDr. Thompson isExperienced. Learn about Adenosine Deaminase 2 Deficiency.
- Aicardi-Goutieres SyndromeDr. Thompson isExperienced. Learn about Aicardi-Goutieres Syndrome.
- Alcoholic CirrhosisDr. Thompson isExperienced. Learn about Alcoholic Cirrhosis.
- ALK-Positive Non-Small Cell Lung CancerDr. Thompson isExperienced. Learn about ALK-Positive Non-Small Cell Lung Cancer.